



EXPRESS MAIL NO.: EL615212745US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Benjamin R. YERXA, *et al.*

Appl. No. 10/010,055

Filed: November 9, 2001

For: METHOD OF DRY EYE DISEASE
WITH PURINERGIC RECEPTOR
AGONISTS

Art Unit: 1623

Examiner: Josephine Young

Atty. Docket: 03678.0023.CNUS04

Confirmation No.: 8525

1623
#C
MW
RECEIVED
SEP 11 2003
TECH CENTER 1600/2900

Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted

herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required, or
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
 - ☐ c. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i), and


- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification..
- ☐ 5. The attached documents were cited in a corresponding foreign application. An English language version of the search report is attached.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- 8. All of the documents marked with an asterisk were cited by or submitted to the Office in Application No. 09/171,169, filed October 14, 1998, and, which are relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 03678.0023.CNUS04.

Respectfully submitted,

Date: September 4, 2003



Albert P. Halluin (Reg. No. 25,227)
Viola T. Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box No. 34
Menlo Park, CA 94025
(650) 463-8109



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO. 03678.0023.CNUS04	APPLICATION NO. 10/010,055
	APPLICANT Benjamin R. YERXA, et al.	
	FILING DATE November 9, 2001	GROUP 1623

U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
*		4,753,945	1988	Gilbard, <i>et al.</i>				
*		4,921,485	1990	Griffiths, J.D.				
*		5,021,043	1991	Becker, B.B.				
*		5,062,831	1991	Griffiths, J.D.				
*		5,169,386	1992	Becker, B.B.				
*		4,380,239	1983	Crawford				
*		4,658,816	1982	Ector, W.L., Jr.				
*		5,345,948	1994	O'Donnell, F.E., Jr.				
*		5,292,498	1994	Boucher, Jr., R.C.				
*		4,868,154	1989	Gilbard, <i>et al.</i>				
FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
*		WO 97 35591	10/97	PCT				
*		DE 23 30 902A	03/75	Germany				
*		WO 98 03177A	01/98	PCT				
*		WO 98 03182 A2 & A3	01/98	PCT				
		08040925 A	02/96	Japan				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
*		Al-Hussein, H., <i>et al.</i> , "Silastic Intubation in Congenital Nasolacrimal Duct Obstruction: A Study of 129 Eyes" <i>Ophthalmic Plastic & Reconstructive Surgery</i> 9(1):32-37 (1993)						
*		Baker, J.C., <i>et al.</i> , <i>Mutation Res.</i> , 208, 87 (1988)						

RECEIVED
SEP 14 2003
TECH CENTER 1600/2800

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO. 03678.0023.CNUS04	APPLICATION NO. 10/010,055
	APPLICANT Benjamin R. YERXA, et al.	
	FILING DATE November 9, 2001	GROUP 1623

*	Bartley, G.B., "Acquired Lacrimal Drainage Obstruction: An Etiologic Classification System, Case Reports, and a Review of the Literature. Part 1" <i>Ophthalmic Plastic Reconstructive Surgery</i> , 8(4):237-242 (1992)
*	Blackburn, G.M., et al., <i>Nucleosides & Nucleotides</i> , 10, 549 (1991)
*	Blicker, J.A., et al., "Lacrimal Sac, Conjunctival, and Nasal Culture Results in Dacryocystorhinostomy Patients," <i>Ophthalmic Plastic & Reconstructive Surgery</i> , 9(1):43-46 (1993)
*	Bone, R., et al., <i>J. Biol. Chem.</i> , 261, 16410 (1986)
*	Brown, H., et al., <i>Mol. Pharmacol.</i> 40, 648-55 (1991)
*	Burton, D., et al., <i>J. Fluorine Chem.</i> 15, 263-266 (1980)
*	Casillas, T., et al., <i>Biochemistry</i> , 32, 14203 (1993)
*	Castro, E., et al., <i>Br. J. Pharmacol.</i> , 100, 360 (1990)
*	Castro, E., et al., <i>Br. J. Pharmacol.</i> , 100, 360 (1990)
*	Castro, E., et al., <i>Br. J. Pharmacol.</i> , 106, 833 (1992)
*	Castro, E., et al., <i>J. Biol. Chem.</i> , 270, 5098 (1995)
*	Castro, E., et al., <i>Pflugers Arch.</i> , 426, 524 (1994)
*	Conway, S.T., "Evaluation and Management of "Functional" Nasolacrimal Blockage: Results of a Survey of the American Society of Ophthalmic Plastic and Reconstructive Surgery," <i>Ophthalmic Plastic & Reconstructive Surgery</i> , 10(3):185-188 (1994)
*	Coste, H., et al., <i>J. Biol. Chem.</i> , 262, 12096 (1987)
*	Dartt, D.A., et al., "Vasoactive Intestinal Peptide-Stimulated Glycoconjugate Secretion from Conjunctival Goblet Cells," <i>Exp. Eye Res.</i> , 63:27-34 (1996)
*	Dortzbach, R.K., et al., "Silicone Intubation for Obstruction of the Nasolacrimal Duct in Children," <i>American Journal of Ophthalmology</i> , 94(5):585-590 (1982)
*	Drutz, D., et al., <i>Drug Dev. Res.</i> 37(3), 185 (1996).
*	Elmaleh, D.R., et al., <i>Proc. Natl. Acad. Sci.</i> , 81, 918 (1984)
*	Foster, J.A., et al., "Results of Dacryoscintigraphy in Massage of the Congenitally Blocked Nasolacrimal Duct," <i>Ophthalmic Plastic and Reconstructive Surgery</i> 12(1):32-37 (1996)
*	Gilbard, J.P., "Dry Eye: Pharmacological Approaches, Effects, and Progress," <i>CLAO Journal</i> , 22(2):141-145 (1996)

RECEIVED
SEP 14 2003
TECH CENTER 1600/2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

03678.0023.CNUS04

APPLICATION NO.

10/010,055

APPLICANT

Benjamin R. YERXA, et al.

FILING DATE

November 9, 2001

GROUP

1623

*	Gilbard, J.P., "Treatment of Keratoconjunctivitis Sicca in Rabbits With 3-Isobutyl-1-Methylxanthine," <i>Arch. Ophthalmol.</i> , 112:1614-1616 (1994)
*	Gilbard, J.P., et al., "Stimulation of Tear Secretion and Treatment of Dry-Eye Disease With Isobutyl-1-methylxanthine," <i>Arch. Ophthalmol.</i> 109(5):672-676 (1991)
*	Gilbard, J.P., et al., "Stimulation of Tear Secretion by Topical Agents That Increase Cyclic Nucleotide Levels," <i>Investigative Ophthalmology & Visual Science</i> , 31(7):1381-1388 (1990)
*	Gilbard, J.P., et al., "Osmolarity of Tear Microvolumes in Keratoconjunctivitis Sicca," <i>Archives of Ophthalmology</i> 96(4):677-681 (1978)
*	Gobran, L., <i>Am. J. Physiol.</i> 267, L625-L633 (1994)
*	Gromada, J., et al., "Role of protein kinase C in the regulation of inositol phosphate production and Ca ²⁺ mobilization evoked by ATP and acetylcholine in rat lacrimal acini," <i>Eur. J. Physiol.</i> 429:578-586 (1995)
*	Grummt, F., et al., <i>Plant Mol. Bio.</i> , 2, 41 (1983)
*	Grymkiewicz, G. et al., "A New Generation of Ca ²⁺ Indicators with Greatly Improved Fluorescence Properties," <i>J. Biol. Chem.</i> 260(6):3440-3450 (1985)
*	Guranowski, A., et al., <i>Biochemistry</i> , 27, 2959 (1988)
*	Hiderman, R.H., et al., <i>J. Biol. Chem.</i> , 266, 6915 (1991)
*	Huhn, G.F., et al., <i>Separation and Science Technology</i> , 28:1959-1970 (1993)
*	Hussain, Al H., et al., <i>Ophthal. Plas. Recons. Surg.</i> , 2:32 (1993)
*	Hyde, K.J., et al., "Epidemic Keratoconjunctivitis and Lacrimal Excretory System Obstruction," <i>Ophthalmol.</i> , 95(10):1447-1449 (1988)
*	Inatomi, T., et al., "Expression of Secretory Mucin Genes by Human Conjunctival Epithelia," <i>Inv. Ophthalmol. & Vis. Sci.</i> 37(8):1684-1692 (1996)
*	<i>J. Physiol</i> 447:103-18 (1992)
*	Kanavarioti, A., et al., <i>Tett. Lett.</i> , 32, 6065 (1991)
*	Kassoff, Jr., et al., "Early office-based vs late hospital-based nasolacrimal duct probing. A clinical decision analysis" <i>Arch. Ophthalmol</i> 113(9):1168-1171 (1995)
*	Kim, B.K., et al., <i>Proc. Natl. Acad. Sci.</i> , 89, 11056 (1992)
*	Kimura, T., et al., <i>Biol. Pharm. Bull.</i> , 18, 1556 (1995)
*	Klein, G., et al., <i>Biochemistry</i> , 27, 1897 (1988)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
SEP 11 2003
TECH CENTER 1600/2800



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449		ATTY. DOCKET NO. 03678.0023.CNUS04	APPLICATION NO. 10/010,055
		APPLICANT Benjamin R. YERXA, et al.	
		FILING DATE November 9, 2001	GROUP 1623

*	Klein, J., <i>Clin. Infect. Dis.</i> 19, 823-33 (1994).
*	Knowles, M., <i>et al.</i> , <i>N. Engl. J. Med.</i> 325, 533-38 (1991)
*	Lazarowski, E., <i>et al.</i> , <i>Brit. J. Pharm.</i> , 116, 1619-27 (1995)
*	Lee, V., <i>et al.</i> , <i>Inv. Opthal. Vis. Sci.</i> 38(4) (1997) abstract
*	Lemp, M.A., "Is the Dry Eye Contact Lens Wearer at Risk? Yes," <i>Cornea</i> 9(1):S48-S50 (1990)
*	Lethem, M., <i>et al.</i> , <i>Am. J. Respir. Cell Mol. Biol.</i> 9, 315-22 (1993).
*	Linberg, J.V., <i>et al.</i> , "Primary Acquired Nasolacrimal Duct Obstruction A Clinicopathologic Report and Biopsy Technique," <i>Ophthalmol.</i> , 93(8):1055-1063 (1986)
*	Lobaton, C.D., <i>et al.</i> , <i>Eur. J. Biochem.</i> , 50, 495 (1975)
*	Lowe, G., <i>et al.</i> , <i>Nucleosides & Nucleotides</i> , 10, 181 (1991)
*	Luthje, J., <i>et al.</i> , <i>Eur. J. Biochem.</i> , 173, 241 (1988)
*	Mason, S., <i>et al.</i> , <i>Br. J. Pharmacol.</i> 103, 1649-56 (1991)
*	Mauriello, Jr., J.A., <i>et al.</i> , "Clinicopathologic Study of Lacrimal Sac and Nasal Mucosa in 44 Patients with Complete Acquired Nasolacrimal Duct Obstruction," <i>Ophthalmic Plastic & Reconstructive Surgery</i> , 8(1):13-21 (1992)
*	McKenna, C., <i>et al.</i> , <i>J. Org. Chem.</i> 46, 4574-76 (1980)
*	McLennan, A.G., <i>et al.</i> , <i>Nucleic Acid Res.</i> , 12, 1609 (1984)
*	Miras-Portugal, M.T., <i>et al.</i> , <i>Ann. NY Acad. Sci.</i> , 603, 523 (1990)
*	Morii, H., <i>et al.</i> , <i>Eur. J. Biochem.</i> , 205, 979 (1992)
*	Moss, A. and Parsons, V., <i>National Center for Health Statistics</i> , 1986:66-7, DHHS Publication No. (PHS) 86-1588 (1985)
*	Ng, K.E., <i>et al.</i> , <i>Nucleic Acid Res.</i> , 15, 3573 (1987)
*	Noone, P., <i>et al.</i> , <i>Am. J. Respir. Crit. Care Med.</i> 153, A530 (1996)
*	Olivier, K., <i>et al.</i> , <i>Am. J. Respr. Crit. Care Med.</i> 154, 217-23 (1996)
*	Panchenko, V.A., <i>et al.</i> , <i>Neuroscience</i> , 70, 353 (1996)
*	Pintor, J., <i>et al.</i> , <i>Br. J. Pharmacol.</i> 115, 895 (1995)
*	Pintor, J., <i>et al.</i> , <i>J. Neurochem.</i> , 64, 670 (1995)
*	Pohl, U., <i>et al. Fed. Amer. Soc. Exper. Bio.</i> , Abstr. Part I, No. 1878 (1991)
*	Portzback, R.K., <i>et al.</i> , <i>Am. J. Opthal.</i> , 94:585 (1982)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
 SEP 11 2003
 TECH CENTER 1600/2900



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

03678.0023.CNUS04

APPLICATION NO.

10/010,055

APPLICANT

Benjamin R. YERXA, et al.

FILING DATE

November 9, 2001

GROUP

1623

RECEIVED
SEP 11 2003
TECH CENTER 1600/2900

*		Rapaport, E., <i>et al.</i> , <i>Proc. Natl. Acad. Sci.</i> , 78, 838 (1981)
*		Rotilan, P., <i>et al.</i> , <i>FEBS</i> , 280, 371 (1991)
*		Sasaki, T. <i>et al.</i> , "Extracellular ATP activates receptor-operated cation channels in mouse lacrimal acinar cells to promote calcium influx in the absence of phosphoinositide metabolism", <i>FEBS</i> 264(1):130-134 (1990)
*		Sasaki, T., <i>et al.</i> , "The ATP-induced inward current in mouse lacrimal acinar cells is potentiated by isoprenaline and GTP," <i>J. Physiol.</i> 447:103-118 (1992)
*		Schulze-Lohoff, E., <i>et al.</i> , <i>Hypertension</i> , 26, 899 (1995)
*		Shermetaro, C., <i>et al.</i> , "Adult nasolacrimal duct obstruction," <i>JAOA</i> 94(3):229-232 (1994)
*		Sillero, M.A.G., <i>et al.</i> , <i>Eur. J. Biochem.</i> , 76, 331 (1977)
*		Silverman, R.H., <i>et al.</i> , <i>Microbiological Rev.</i> , 43, 27 (1979)
*		Stepinski, J., <i>et al.</i> , <i>Nucleosides & Nucleotides</i> , 14, 717 (1995)
*		Tarbet, K.J., <i>et al.</i> , "External Dacryocystorhinostomy Surgical Success, Patient Satisfaction, and Economic Cost", <i>Ophthalmol.</i> , 102(7):1065-1070 (1995)
*		Vallejo, <i>et al.</i> , "Dinucleosidasetetraphosphatase in Rat Liver and <i>Artemia Salina</i> ", <i>Biochimica et Biophysica Acta</i> , 438:304-309 (1976)
*		Vincent, P., "Cationic channels sensitive to extracellular ATP in rat lacrimal cells," <i>J. Physiol.</i> 449:313-331 (1992)
*		Visscher, J., <i>et al.</i> , "Selective cleavage of pyrophosphate linkages," <i>Nucleic Acids Research</i> 20(21): 5749-5752
*		Vovsi, B. N. et al , " Importance of hydrodynamic indices for pathogenic treatment of penetrating wounds of the eye", XP002035486 see abstract
*		Walker, J., <i>et al.</i> , <i>Biochemistry</i> , 32, 14009 (1993)
*		Young, J.D.H., <i>et al.</i> , "Congenital nasolacrimal duct obstruction in the second year of life: a multicentre trial of management," <i>Eye</i> , 10:485-491 (1996)
*		Zamecnik, P., <i>et al.</i> , <i>Analytical Biochem.</i> , 134, 1 (1983)
*		Zamecnik, P.C., <i>et al.</i> , <i>Proc. Natl. Acad. Sci.</i> , 89, 2370 (1992)
*		Zatorski, A., <i>et al.</i> , <i>J. Med. Chem.</i> , 39, 2422 (1996)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.